Eli Lilly Cuts 340B Pricing. Plenful Automates ESP Submission

Eli Lilly became the first drug manufacturer to follow through on its claim data reporting policy, cutting off 340B pricing to specific covered entities that failed to comply with its in-house pharmacy claims data reporting requirements. 

‍

ESP reporting is now essential

‍

Lilly is one of 11 manufacturers who announced plans to require covered entities to submit in-house 340B claims data as a condition of accessing 340B pricing. Lilly's actions set a precedent that other manufacturers could quickly follow.

Novo Nordisk set its in-house pharmacy claims data requirement effective April 1, 2026. UCB followed with an effective date of June 1. Biogen, Bristol Myers Squibb, AstraZeneca, and others have issued their own policies. The direction is unmistakable: manufacturers are treating ESP reporting compliance as a prerequisite for program access, not a courtesy request.

340B Health, the American Hospital Association, and provider groups are pushing back. They argue these requirements violate the 340B statute by adding conditions that effectively raise costs above the statutory ceiling price. HRSA says it "continues to review these policies." Until a legal or regulatory resolution emerges, affected covered entities will need to comply with claim submission requirements or forgo 340B savings. 

Submitting claims will be an additional data challenge and resource commitment for pharmacy teams already stretched thin. This becomes magnified if additional manufacturers follow suit.

‍

Plenful’s ESP reporting automation reduces submission time by 96%

Reporting to the 340B ESP Portal requires significant manual work. Each submission cycle involves extracting, validating, and formatting claims data across multiple drug-specific eligibility rules — while accounting for the strict qualification logic set by each manufacturer.

This time-consuming, labor-intensive process now carries real financial consequences if it fails.

Plenful automates the full ESP reporting cycle. Behind the scenes, our platform continuously audits 100% of 340B claims, applies manufacturer-specific eligibility logic, and generates the submission files your team needs. For manufacturers that have opted for Truzo, Plenful provides a seamless integration for claim submission. 

‍

Leading health systems like Samaritan Health reduce ESP reporting time by 96% with Plenful

With Plenful’s workflow automation platform, Samaritan Health Services, a non-profit health system operating five hospitals and over 110 physician clinics in Oregon, cut their ESP reporting cycle time by 96% — from hours of manual spreadsheet work to approximately 15 minutes per bi-weekly cycle. 

In addition to time savings, Plenful’s report is more accurate than what Samaritan could previously produce manually. Accurate reporting ensures maintenance of their 340B drug pricing, securing millions of dollars in critical cost savings and program benefits.

As Savannah Randolph, Pharmacy Services Analyst at Samaritan Health Services, shared:

‍“What could take a large team many hours only takes seconds with Plenful… and the report is more accurate.”

‍

​See how Plenful’s automated ESP Reporting can help you stay ahead

The administrative burden of manual ESP reporting will grow as more manufacturers follow Eli Lilly's lead, making the transition to automation even more urgent. 

‍​Request a demo to see how Plenful's ESP reporting can streamline manual work and maintain your program savings.